CRL

Business Profile & Competitive Position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. In practice, the company is a full-service, non-clinical drug-development partner: it supplies research-model technologies, discovery and safety-assessment services (both GLP and non-GLP), and manufacturing-support products. Its three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.

For the full year 2025, total revenue was $4.0 billion, with DSA contributing 59.8% of sales, RMS 21.1%, and Manufacturing 19.1%. The company runs more than 120 sites across more than 20 countries, giving it broad geographic reach. Yet the current profitability figures do not point to a strong earnings-based moat: net margin is negative 6.0% and return on equity is negative 7.7%. A negative ROE means the business is currently destroying shareholder equity on a trailing basis, while a negative net margin shows revenue is not covering costs. Scale and an integrated portfolio can be competitive advantages in theory, but the margins indicate that those advantages are not presently translating into bottom-line profitability.

Financial Posture

Charles River Laboratories carries a market capitalization of $13.0 billion and trades at a negative P/E of -55.7. A negative P/E simply reflects that the company has recently reported net losses; it is not a meaningful valuation multiple in the traditional sense because earnings are negative. The net margin of -6.0% and ROE of -7.7% reinforce that the firm is in a loss-making posture on a trailing basis.

The stock’s beta is 1.41, which means it has historically been materially more volatile than the overall market. As of the latest snapshot, the price was $269.695, the 50-day exponential moving average was $260.51, and the RSI was 45.3. The fact that the current price sits above the 50-day EMA while RSI is near neutral territory is a descriptive snapshot of price action, not a directional signal. Investors looking at this name need to weigh the company’s scale and strategic repositioning against the reality that recent earnings have been negative and the shares carry above-market volatility.

Strategic Priorities & Outlook

Charles River’s most recent 10-K filing outlines a near-term operational agenda centered on footprint optimization, organizational integration, and portfolio expansion.

• Footprint optimization: The company plans to close or consolidate approximately 12 additional sites over the next two years, mainly within the DSA and RMS segments. Restructuring on that scale is likely to generate near-term costs and charges as the company shrinks its physical footprint.
• DSA integration: Discovery Services and Safety Assessment are being folded into one DSA organization with a combined sales force and leadership structure. The stated goal is to simplify client engagement and cross-sell integrated non-clinical services.
• Scientific partner of choice: Management continues to emphasize a comprehensive, integrated portfolio designed to speed biomedical research and therapeutic innovation.
• Biologics testing expansion: The company is seeking to expand Biologics Testing Solutions facilities and service offerings in both the U.S. and Europe.

On the M&A front, the January 2026 acquisition of certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, is aimed at supporting DSA supply operations and RMS third-party sales. The strategic picture, therefore, is one of consolidation and integration rather than aggressive greenfield expansion: fewer sites, a unified DSA go-to-market model, and targeted tuck-ins to secure supply for research models.

Macro & Geopolitical Exposure

As a Healthcare/Medical – Diagnostics & Research company with global operations, Charles River faces several macro and geopolitical forces that are relevant to the broader industry.

• Regulation: Non-clinical drug development is governed by strict GLP, animal-welfare, and FDA/EMA rules. Any tightening of standards around animal studies or biologics testing could raise compliance costs or delay studies.
• Supply chain and trade policy: Research models, non-human primates, and specialized biologics reagents move across borders. Tariffs, export restrictions, or logistics disruptions can affect availability and input costs. The Cambodia acquisition underscores the importance of research-model supply-chain security.
• Currency: With operations in more than 20 countries, a meaningful portion of revenue is likely denominated outside the U.S. dollar, so exchange-rate swings can affect reported results.
• R&D spending cycles: Demand for non-clinical services depends on biotech and pharmaceutical R&D budgets. Those budgets are sensitive to capital-market conditions, interest rates, and funding availability for smaller biotech clients.
• Labor and facility costs: Running high-complexity laboratories requires skilled scientific staff; wage inflation or talent shortages in specialized fields can pressure margins.

Recent Developments

The most recent headlines, all from September 2026, have centered on conference participation and a notable institutional sale.

On September 14, 2026, a transcript was published from Charles River Laboratories’ presentation at the Morgan Stanley 24th Annual Global Healthcare Conference, according to Seeking Alpha. Earlier, on September 11, 2026, both GuruFocus and BusinessWire reported that the company would present at the Morgan Stanley and Baird conferences. These appearances typically provide management with a forum to discuss backlog, pricing trends, and the progress of the site-consolidation program, but they do not by themselves change the financial outlook.

Separately, on September 10, 2026, DefenseWorld.net reported that Amundi sold 360,913 shares of Charles River Laboratories International. Large institutional reductions can reflect portfolio rebalancing or a change in conviction, and the timing—just ahead of the Morgan Stanley conference—is worth noting from a sentiment standpoint.

Earnings Behavior & Post-Earnings Drift

Charles River has a strong recent earnings track record against published estimates. Over the last eight reported quarters, the company has beaten consensus earnings expectations in all eight quarters, for a 100% beat rate, with an average earnings surprise of 9.3%.

The average 5-day price move in the five trading days following those earnings releases has been 1.24%, classified as an “up” drift. That said, the drift has not been uniform. Looking at the most recent quarters, the August 5, 2026 report delivered actual EPS of $3.02 against an estimate of $2.74, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five days. The May 7, 2026 report also beat, with actual EPS of $2.06 versus $1.96 (a 5.1% surprise), but the stock fell 2.23% the next day and dropped 12.42% over the next five sessions.

Before that, the February 18, 2026 quarter produced a 2.6% beat ($2.39 actual vs. $2.33 estimate) and a 3.95% next-day gain with a 6.05% five-day drift. The November 5, 2025 quarter delivered $2.43 versus $2.32 (4.7% surprise), with the stock up 1.9% the next day and 2.27% over five days.

The next scheduled report is November 4, 2026, before the market open, with the consensus EPS estimate at $2.96. The historical beat rate and average surprise suggest the company has regularly cleared the official consensus, but the mixed post-earnings price reactions show that beating estimates has not always produced sustained upward moves.

For a deeper dive into how sell-side and institutional models are interpreting these fundamentals, conference updates, and the upcoming November 4, 2026 earnings report, readers can review the full institutional verdict and consensus breakdown for Charles River Laboratories.